Polatuzumab Vedotin Approved in Europe for Relapsed/Refractory DLBCL
The European Commission has granted a conditional marketing authorization to polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma who are ineligible for hematopoietic stem cell transplant.
Source: OncLive